<SEC-DOCUMENT>0001193125-13-151831.txt : 20130412
<SEC-HEADER>0001193125-13-151831.hdr.sgml : 20130412
<ACCEPTANCE-DATETIME>20130412060924
ACCESSION NUMBER:		0001193125-13-151831
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130412
FILED AS OF DATE:		20130412
DATE AS OF CHANGE:		20130412

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13757415

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d520948d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Form 6-K </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the month of April, 2013 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Novogen Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(Translation of registrant&#146;s name into English) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3">1-7 Waterloo Road, Macquarie Park, NSW, Australia </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Address of principal executive
office) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or
will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form 20-F
<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%; text-indent:-6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1): <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%; text-indent:-6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%; text-indent:-6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%; text-indent:-6%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a
report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home
country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:6%; text-indent:-6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant by
furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes
<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No <FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Limited </B>(Registrant)<B> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Andrew Bursill </U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Secretary </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date 12 April 2013 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>


<IMG SRC="g520948img1.jpg" ALT="LOGO">
 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12 April 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ASX RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen announces placement of stock to raise $2.5M</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen today announced that it had received acceptances to raise $2.5 million by way of a placement of its shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The placement has been managed by stockbrokers, Patersons Securities, and is subject to the various approvals being sought at the upcoming General
Meeting of Novogen on 19 April. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares will be issued at a price of 16.6 cents, being a 20% discount to the closing price of 20.5 cents
on 10 April 2013. The number of shares to be issued represents approximately 15% of the outstanding number of shares, which subject to gaining shareholder approval at the General Meeting for Resolution 2, will be 119.3 million shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The placement will take place immediately following the general meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purpose of the capital raising is to allow the Company to move forward with its drug development program and to provide working capital. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr Graham Kelly, Novogen Chairman and CEO, said, &#147;The funds are designed to take CS-6 through its pre-clinical program in preparation for both glioblastoma and ovarian cancer indications.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Our strategy is to raise monies over the coming 3 years on a progressive basis rather than in 1 upfront raising, in the expectation
that progress in our R&amp;D program will be understood and appreciated by the market on a progressive basis, thereby minimizing shareholder dilution.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;To that end, the directors of Novogen also are considering offering shareholders a Share Purchase Plan. They expect to announce the plan shortly.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOVOGEN LIMITED </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ABN 37 063 259 754 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level 1, 1-7 Waterloo Road </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>North Ryde NSW 2113 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Novogen </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol &#145;NVGN&#146;). The Company is based in
Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company&#146;s inaugural drug candidate is CS-6. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CS-6 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CS-6 belongs to a new class
of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells &#133;. cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer
cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme,
the main form of primary brain cancer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Cancer Stem Cells </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a subpopulation of cells within many types of cancer that are responsible for driving the growth and spread of the cancer. CSC
typically are resistant to radiotherapy and chemotherapy and are thought to be responsible for cancer recurrence following therapy. Targeting CSC is a new direction in oncology drug development as a means of preventing cancer recurrence. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Further information</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact Dr Graham
Kelly, Chief Executive Officer </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: (61) 0459 200 095 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">E: <U>Graham.Kelly@novogen.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information is available on the Company&#146;s web
site <U>www.novogen.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOVOGEN LIMITED </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ABN 37 063 259 754 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Level 1, 1-7 Waterloo Road </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>North Ryde NSW 2113 </B></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g520948img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g520948img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P"N`P$1``(1`0,1`?_$`+@````%!0$!````````
M```````#!P@)`0($!@H%"P$``00#`0$```````````````,$!08!`@<("1``
M``4#`P($`@<'`P4``````0(#!`41!@<`$@@Q"2%!,A,B%%%Q@:$C,Q5AD=%"
M4D,6L208P>%R@D81``$"!`,%!`8'!`@'``````$"`P`1!`4A$@8Q05$3!V%Q
M@3*1H2)",Q2QP=&"(T,(4F(5%O#Q<L)C)#0ELE/#1%0U%__:``P#`0`"$0,1
M`#\`[^-$$#1!`T00-$$#1!`T01KETW%'6M`S,_+.T8^,A6"TC(OG`?@-&C<@
MJ+.%1K^6D0!$1\@#64`N+Y:?-&%%#8"G%!*293.R/8;K$.41#Q]/Q%H)3`)0
M$!+0P@'7004F1@F"2!L&_<>Z,O6(S`T00-$$#1!`T00-$$#1!`T00-$$#1!`
MT00-$$#1!`T00-$$6B<H=1Z_7HV;8S(SEO@;R_3]P_PUC,-D$CLBNX*5KX:S
M&%>SYHKH@BP5"%&@F`!^C60E1V"-<R)R*DS[Q#?N4D2>Y..'(*#;J&26E,+9
M.8-UR")#).5[*FR(JE,%#%.FJ("40Z"`"&EZ-*DU8*O(9#TF406I$*J+'6!M
M65QIHJ20=\I_5$8O9=[E]J<V./=O6)>,TQ9<E\1VS"0>1X!PI[#R\8F-9HQD
M7D^!;G$!>,9I)%,LB5.IF<AO*<"D.F(REVMK]/E>RGDJ$YQ1^FNO:34%M_A]
M6ZD7-A63*9S4..R43>%.4U-HUJ&X/JZ5U!C$3&R.K$@+R'S2G%1$``1'H&B-
M@)F0VQ;O+2M?"E>@]/W:#@)G9`01MBSWTOZ_N-_#0C\3R8Q@R&TI](^V#0,`
M]!_;H@.&)BNB""S*D*-#&H/U&_U`*:V"5$3$&'$>D14JA#`(@/@'4:"'^H!K
M!!29';`HA(F2)=\_HBNXM*U\/J'^&M"I*=IC4*!$QL@;R_3]P_PT)6E1D#C!
MF`VQ05"!Y_</\-*950H$*.(BN\OT_P"NDUK2C!9E&""-L5W`/GHS).^`@C;%
M=;3W[HQ!:AMNT?#J/7ZM9W3,!D$*4=PA&<JYZQ%A%C%2>7<CV9C6.FGZ\9$/
M[SGH^`:23QND5PHU8KR"Z)'"Y43;A*41$`\M(/O,,B3RT(GLS$"?=/;$C8['
M>-1J73VRFJ*A]&)#3:UD#B<H,O&%1C9>,EX]E*1SQ!ZPD&B#YB[;+)KMWC)T
MD1=LZ:KI&.FX;KH*%,0Y!$IBB`@.L)$U#+COPAI5,/6]:VJ@$.-JRJ!!!2J<
MLI!Q!GA(XQI=PY;QO:EY6ICBX;YM>%R!?B3U>RK,DI9FUN.ZDHT#'D%(.+65
M*YD4V:9#"J*91V4\=*%QM"@A:DA9V`D3/<-L;LT=954ZZMMIU5(V9+6$J*$D
M[`I0!2DG<"9PH!GJ8%^$!WB`;0-0H&$?H$1ULHA`S*,D\3@(:J4E&*R`)RQX
M\._LAG^3N>?#O$%QKVMDKDAB2T[C;+$1>03Z[8U:38JJ5HF^:LE'*C-0!``,
M53:8M0$0U'JOM$THMYT3&'F'VQ<K;TTUG=F14MV=_DK&9"U@HS@[%#.!,':)
M0K-B9=P_GNU7\EC2_;/R-:<HV7B7C^U9V.FFA4I!%1!1-Z#5=11L91!0P;%2
MD$0Z:<4EQ;J'TK:4E29[B#V[HKFI=&WBP4[E%?*==&7D$'."$R(D"%&23.>X
MF/F42MR9;X-\OKX<XWN*1L/*>`LSWU!1DHS,HGM2@;JD&81LHR.<49*WI^)(
M0CIJL!DG#=40V^!1#L].RBOMR6G4DS3@91\W[M5W70^N*I%(5!+3P,@#B#O`
MWCMV1]#3MJ\^+*Y^\>HK*L*1K!WQ!&;VMEJPR+E7<6??39JFL\!L85/<<6W/
M)_[R,7$`$R!Q3-^(DH`<TNML-OJE?\LQ[4Z?:Q8U;9D5$Q\RD#-B)P^^[;OM
MRR;:F;MNN:C;<MNWF*DK.3LT[;QT5$1K8/<=/Y%ZZ52;M&B"91$ZAS`4H>(C
MJ,F`)D@)XG9'1J6B?KWTTE.E2GESD`"298X`1Y=J7_:%]6I%7O9]Q1%SVE/Q
MYI6$N6%?-GD'*QE5`^>8R*2AVR[,/:-^(4PDH41K36O,;RYR4\OC/#TQK54M
M52O&B*"NNV!OWB3@!+;CW0U2[>XKP=L>X%K5NOE#AZ*N!JN9HZBCW='NU&CH
MAQ3.@Y68"X01.0X"!@,>H#X#IHY>:)D94*01V$?;%TI>DNO[C0"N39'@T1.:
MII'KE#H+$R=8F2K?8W;CV[[;O6UY,F]A/6S,Q\U%.2B4#43>,'*Z7N%H(&*(
ME,6GQ``Z=(>:>$V5(7+;E(,N^6SQBHW.QW&Q**+FVZRX!L<2I![_`&@,.T81
MO@NT@(41.2HB`4W@'7I3Q'K7PUM,9<_N'?N].R(]+B2A*YB2C(=IX#B>R&H9
M9YQ\1\*SBMNY3Y"XJLN>1`GO0TK=D<,JVW=`=L6JKAPS'P&H*E*8/HII@Y>J
M&F<Y2W6YC]Y/VQ=K/TTUGJ%GYZ@M3[M&20%E)2"1M`S``R[(V[$7*GCIG<[A
MOAK-.-\CNFY`4<L;5NF,DI)NG4`]Y6,*NF_!$!ZG!,2@'C76S5QIZWVF%I5E
MX$'ZX87O1&IM,(_WRWO4B5XI*DJRJ`V^U++AWQM.5<[X>P;'1,KF+)5E8UBY
MMZK'1$A>=PQMOM))^@@=RLU9+R#A(CA9)N03B4HB;8%:4ULNLIZ:2WU)2%&0
MF0(9V?3]ZOB5ILE.]4N-IS+Y:%+RIG*9R@R$R!,X0B:O<&X1I)&5'E5@C:0@
MG.)LD6V4I2%#<<QA%]4`*4!$?JT"Z4)(',;!/[PB6_D+6F0N5%NK!3`&9Y*Y
M"7;*4+_<66L=VE8:F3[DO2VX+'B4:PF3WK+2K-C;:<3*E;&BY(\LNJ5I\G(?
M.)>T?>`']PM*UTHJK;""LJ`1+;/#TQ7K?:KA7W`VFC;<=K3,!M"2I9XD)$U8
M=THS;`R78N4;7CKUQ[=L!>EI2XK!%7);4HRF(60%LJ=NZ!G(,5ED%A;.4C$.
M`#N*8H@(:U8**U.=I25IWD&8](A6ZV>XV&J-#=6GF*X#-RW4J0L#<<B@%2[9
M2C`R3ES&N'8F/N#*5^6K8,+*S#*WHV2NR:8P;![.2(G!E%MG;]9%%5\ZV"*:
M8#N,!1^C6RU(:EG(2#Q,I]TX;6RT7&Z.%NC:=><"9E*$J60!O(2"0.W="B?.
M(_I_S_NI_+_+?->]N#VO8]OW?>WUV^W[7Q5K2GCTTMAE[(3Y)YO(WYLOCL^F
M#7(5('_D&ASX2AV0UJ/@$=H^D1SU=^>SXJ_6/!BQ9O<6(O+DNA:DFHA\#@C"
MY(U")>*(*4,8CA-N[,)!Z;@`!\!U1-=4K]8FD8I_BEP$>$B?5'K3]+MS7:*[
M4%R1YF;>%#&6(F84;M=YNOC$U\Y"[:G(E^LIE3CT<SW$$_("I7(F$'"GS$&I
M&NG(BH]5M^/5)[=!,;Y0VP0_VYZ2%BKW17FAJ#^(E$AV[HJ/5^P45]MS/533
M:2--53H:JN`K#L!X$JX[P.,$\S-BG=^[8*VP#&_Q;,0$,8A=Y*-7_P`1#"`B
M43`%!IU#2MY$]0TX[(;Z-:(Z+ZFGL%P:GZ1&T=WSDCE>T('!_$_CK*N8'-?+
M.\U+.8W(P7%K(6U9R"K&/F7C!VD8%F+M\ZE4R"X((&0:I+F(8#[1#-\N"@^+
M7^W(0\Z":-L=94W'6.L&/F],6RG6M23Y34!)*)]QD>^%RXU=J;B%Q_L*/@GV
M*K0RQ>S]@D2]LD9(M]A=<_=,NNGNE79?U@K]*,CW#@Y_;01`H`2@G$ZE3BM3
MZ9M893S`GF91.?&*-J;K)KF]5?,8J7*>D"CD:2H@-IG[*<.`E$:G/3C,/;#O
M"U>?G"YN;']E1=W0-O\`(+"44N\)8]S6Y<#P&WSC:(.LJV9-G:Y`;&2*`?*N
M5DG#<4Q!0#P]XHTV(HK:'!J>[UQVGIAJ6GZP6RKZ4ZXI_FKD\RIVDJ")J"TB
M<I_N^&&$0Y]_/C<C;_("P>9EB,#FQ!S&LBW;N+*I(A\I'Y(:6\R._CWAR4;H
MN[BM@&D@F`T]]5-T(5,`Z[UHV^+JZ%MM9]U,NS#Z(^1OZB^G]STSJNHN14>:
M%+:7N(*%90/1ZI0C/8QY9ON-/.VQ+:D9%9MCGD2HCA^\VBJQ@8)S\LJ8V.[B
M5;C^$5U%W*)&GNB&XC5\L6M!`-/M36SF4;C^^4_MBH]%-3OV#4S=EKL&*H"7
M]HD'Z(ZM.\O?$_.X=Q1Q"L5RJAD#F7EJV<7)(MA'WT++9OVLE>T@L)/B*P10
M!!-92@E!)0X>(5UP753U2FF8HJ0_CK<0/"8S>J/J_P!"J!A55<-95S8<MMII
M'5$']M:"AO'B%&<-RY[R=]7%DOB?VA>,=RN<<0MUV-$.,M75#G,V=P>*+?9J
ML$H=,[-5!9-%S&0+EZ\3(8OS9_82,.Q4^Y&ZN+J*UG2]ND'`D*<_L@8^J+CT
ML;M%)9[IUEU91\XLK<^421YGA,H[_:DGL`,20XD[8G"3%5@-\>QG'G&]PMBQ
MQ8^9N&\[:C;JN:YEO;*5>3E9N6(Z=_,N#ANV)"DFF'PD*4-2]+8:&D3_`)A(
ME/?C_3PCD=\ZKZ^N%Y-V8N;K-*22*9"BE*0?="9R,NT&<1+YNQFX[//*G#^<
M\".9:.XAY^OM#'N9<,KR#I];EI3$@H04)R!([<+`S3!F*KMB:H+-U6RC8QA1
M4(!*]4%=@NR*ZC_]74J"5`=L=MTM74?6_0MPTMJ5H(U-:65/,U1&+TA,(/&9
MP.XP]/NN\E\L67`8.XN<;I7](SGS"NQ.R(&ZFQQ(ZM.S%#M&DY.1S@E#-'CH
MT@1-)R6IVZ!%SI_'M$)'4E8]1ENCI_@.2">P&*+T/T5;[B[6ZQU73A=AL04^
MZR922XG$(X2GZR(5_CAVGN'6$K.BF<YB.ULPY"62(M>F3<J1Q+VN2Y)]0M91
MZ!ISYU".;JNQ,*:210VDIN$QZF%2EL-%3,I14TX<>(S3/;C%?U3UCUC?KB]4
M62I5;K0MPJ:802D)3N.!VG?QA<["[?O$K%&88W.V*\(V=CK)$9#S$$UE+09'
MA8\6D\1%.354@6BZ4,+U1NC[95P0!4I#G`#?%J3I;;1M+ST[(:&_MBJ7OJ!J
MZ^68VF[UCE6W[LS/+V3[XCM[TL!"71=?;IMFYHB.G[?G.85L0TY"RK5)Y&RL
M/(),6TE'OVBP&3<LW;94R:I!`0,0P@/AJ$OXIB\RU52R<S#T1UGH$Y<+?;-0
M.4#I:J46>9*3(G\5.'IE#^5>VYP),F%>(V`]JH^`&QU`T.3J)=ORM-J@>%/,
M!U+"TV=3:5E*<H/#MCF=5U/ZE)9<99N+ZZ?*H*25;01(X`2A"N[M"Q-N=LCD
M1#0<:QBH>!LFV(V'B6C4J,>PCXR[;808,$&E`329LT4BD(F``4I"@`::ZJ;0
MS9UHIA(<L_08LG0>H=_^OVNXJ)^<4TLK.^4L?5.(Y>W[>=P=O7,V)\`9$E7J
MW&'FO8-FY/P5<\HL<["R\OW!;,*XN>R%G:@^RU3FY-R)`#P!119LK2IU1"`L
MK]597Z6S_P#EI!\3_3Z(Z]U4H*?JO9;EJ6@$]<6=]::F6TTJ5$`^`D?2(<_W
M]2HK<5L+@<J9S!RKQ5X4`PT*WG0,/EM'PI]NI+5::H)IP/VXIGZ96EC556*B
M<OX8[_PF)M]A0LGV=OP#;.W;4?0$4'P5Z^GPU8Y+^1_Q.7]4<,RM_P`PY<.5
M\YX2YD;.OZ0^O3ISX:NZ()[X1\/I$0']['PNCMT;O$/^7]J5\^KB++_UU3]6
MY@_193(\P?5'J#]/H2;?JPG#_95R[\BI>N%7[K/&6^9Z'LOFAQW;&9\EN*3D
MUWQ@L$SB[O?'S(QW=SV<]3;;5Y%(K7W5DD1$142.X2#Q5#3V^4KK#J:^C`YS
M+96)"4\HG(\?7%5Z):QHVWG-'ZJE_+]Q"VBE>+:5K&5+H2KV0L&12N0*5`$&
M<,JDN2MD\MNX#VBLW6.Y#Y&Z[`RZWG8<RA1>6O=S./>-[CM=Z4!J1Y&OC_AB
M(`*J!B*!X&#4`Y7LU]YI7@J5?*>7@=XE'03HRNTETFU=;JM*O\M=FG65'\QI
M1]D]HD?3"G]U*1:X6Y\]MCDS=H*H8OMN[)ZQ;BE3`(Q\&]DW351)T^.8HHH%
M*QDU'`FJ4=C4PA6E-/=5M<JXTE6K]L3],->B%6W>>F.I-',$B\U[1=;0-IRI
MG@-\R)1T%L9%F[:-%VBR#ALY116;+H'34;N$E4RK)J(*$,)5$CIG`2F`:&`:
MAX:NZ2%@+XB<>4JIBKMR^74@\\$A4QB"#(@SQGNXQ#=WSLKVQ9O!J_[!?&9.
M[PS1,6M8-D0!CE4D9&1+-L)>2>LV8#[YSQ,<PJ!R%,`*+)EZG"M4UBX'+8FC
M3YROZ>$>A?TU6BMJNI%/?:G,W:;?3NN*4"0/*=I[9>J%T=\&;*Y"=N_''$'.
MK!50&V%L?0BTL1%,\W8]_0EN,QC[EA5#E."4Q;,B(E&A@*ND!D3_``',`V+3
MSSMMI:=*9F:,<>$<%ZOT%MZA:@NBTR^5JJITI)D9241,&.!'EEQ.SKV[.1;6
MR,FQRB$M:D]%WKC._8A%=*VLB0EO3361BKIMAV>M'"1VJ:;QB<WS#%U5,X4$
MIS]FI:YBOHLJ3-24DD''=+&/GI>--7/0>J@^I*C0M.#*LX^8Y0)]DYB4=D'&
M:XVW.[N7S'(E`OZMB?B5@ZR;+L9VH(+L'.6<IVRSN*ZY!N01,B1[%,I%PW.)
M1W$,B0!\=<`^7-7J-^H_+:5(<`2981]:TU*M&]#[;8A,72Z%#RR#)2VS+S':
M1*6!F)XQK6;9MIQ^[[^$,B7^*,?9.?\`!88UMBX'X%0B&5RD(^AT8X7ROX"3
MI249,T3";;3]2)4=0S@-NU7\P3BM($\9RX3B]6%Y-\_3M<;/:YN5]'7AY24G
M&0)49`;I'TB.A)LN58RARDH)!`HAZS;@`!$H"`[1$OG2NKRT\*I,I8>J/*[J
M:=A7.6A?S9&S&(`^_#<\5=N-^-_&>WA*_P`JY@Y!6:[MV`:'(M(EB(@SB+7E
MW*!045;L1E9M!(#B!0,('$!'VS4I6K$"I8IK12',\VZ%$#=*/4_Z::9R@J[W
MJB]I*+#;Z!:4+/E6XI)RI,\"=\HUON;C_P`>>:G;/Y/W2!U,7V!.*8PO"<7#
MWF=OO72:)"R3LZI=C056CMPX!0?$09F``K2N+TPLW>AJ'IR#8F)[##SI2\QJ
MS0>I](L*R7:L>6\@##/C,),I3&$I;!,1T*0CZ/DXMM)1CE%Y'R"97K%VU535
M;NVCDGO(.FRJ)CIJ-ETCE,F<HB!B"`AJY4]3\RX5I/L@9?1'E>J8K*1QYBN;
MR.-$HD1(C+AX1'/EOEODNRNX[QQXC1$;:RV.LP8LO6]+DE7C=^:Z&4Q;:<TH
MP2B'B;TK!!FJ,:F"A3H*&$!'QTT<JLEP12SQ<!/HCHMJT127+IU6:G4HI72N
MH1AOS"<,[[WUJ,;ZF.`5C2+Z6C&%Y<JX2VG\E`R"D7.L&<VT:1KAY#2:("K'
M2:"+DQD5R!O2.`&+XAJOZI82^6&%X`.SGX<8ZE^G*\U5EM^H+E2I;6MNTX!:
M0H&3J<"#.')V'VE<-8ZOJS+_`(K.G+:8D+/N*+N9E%7/GFXYBWW[N*<E=-F$
MS$K(@C)1;E4H$61/0%"#0=2E+94M(2^%*,@<"<-D4N_=;-07^VU%-4T="CV5
M)_#80@GB9@3V8QZW>1+O[;')\QJ`<+5A-H!7:<"W=;H`(!_373+4[*_Y;*0<
M2H>N<(=!'DL]7;95->TZMI8(.,II(.'C&O9-XB0?,OMKX1QFHH2&OV%P?BJ\
M<27B`@@^M+(L-8\4XAGZ+PIB+HLI`^YLZV&+N24$?44H@\5;S66JE:'^H"4R
M5[PD!OVCTP6S7#FC.J51<7232.7)Q+J,2EQ&<S"D[%@#<H$;I1"ORQY=S/(_
MM_8PQ_EY-:&Y0<=N7V*L89QMQ_1-^M(PI+BCXZ\O:$B8J-[C19?BJE#8+Q-3
M;4IBUI]QNBS\O254PH.2,SVRG'H[IYH5FP]2J^MLZN;HQ^UO.M/#RS6C-E"M
MF!5@(Z]__CP\2T_QH?'<&RGZ2'CNK3;^WIKHV5OY7)/\/)M[);8\49O]^S2_
M[S_JQ[[H1$"@4U!`1J`?M*-!^P=+':`1-$\>Z(4B;B,WPI^T.(E]L1C]PSAU
MD?EE-<49&P9RUH5+!N>(3)USENA212&3@HQ5H==G"C'M'1329OEZE]X4T^E1
MU!WR@56U#2DB:6U`QU3IEKVETI0WIFJ2<U?3%I)END0/#&))SH%6(N!B`8BP
M'!0JA04`Q1$0$J@#\`@8G@(5IJ>6`XVA*Q-6PSX;YQRINH6MKFB8=;<)3N(3
M.?T1S^6?VD+[Q!W*[-Y*8KEK7:<;8^[+BR`XLIW*/&L[:=P7C`R3.XXNVH1)
MFI&'B5)<4%D3^ZF8B1_;H()EUSMO2SS>JOXNV9)!P/#N&R/5-P_4';K_`-%Z
MK1MV9YFK'4H2*DCVRELC*"1($R$L1XQ,#RAXR8SY98>N3"V588TC;EPD26:O
MFRA$9FW)IJ"@QUQP3P0'Y24CC*FVB("FH0QDU"F(<Q1O%PMK%T8#;X',&PG=
MVB//NA]87[16HFM16S\(,IRY1L*#YDD&>"A@=_"(IL?\=.[WQ&ADL7X+R]Q^
MY%8JB4CQUD.,V-[B@KRLV)1*=./8JNF!CB_0CDS`":1EET2E#:0I"4*%<-'K
M)A7(I7:,TR,$E<\Q3NGVQVZHU7T,ULY_%=46^Y4%R4<RA3K3RW5G$D`S("CX
MQMV&>VCF3).?+=Y5=P_,<)G'(5E*HN,=8MLZ-6C<2V.[;N4WK-P+-ZFB,BK&
M/R`LF0J)"G73356.L8A-J[%EN;[@K+ZXVIT'!*/(`-A';Q$,=1]6+19M/N:;
MZ9V]=NI74*0XXI04\ZE8DH*5C@H;\"!@,8FY;)`4I@*4H"`_%M/NJ(AYC4?&
MFK(UG2G(2<@P'='G9AI;;24N("#B9">\S/KA@'<BX*6%SKXV7/BF7CXQC?D:
MV?W+A^]#HID>V=D%JQ4"*53>"0RJ4+-F`K.21`=BK4]1`3)DI*4-=44BEEE9
M3F3(]WC%4UEI2@U/:C3U+:%EM:7`#O*3A]L:/VH>&MR<)>)=HXQR`A%I95F'
MTC=N4U822)-1G^2/S`R9QS*8(@V_4F<1",VR)513+N-N$`\1U#944]0IY"?,
M9JEO_J,=$K]07#4%NMJ*MQ1704X:`,L$I24@88;QZ,3"L<X^$&,^<&+RV'?"
MCR!G(1_^NV#?\*1+]?LRYB$*4K]D*U"NF#L$TRNVIQ!-<A`&I%$TS@C<+93W
M1'.0`*I(P5OF!@(LG3O7M1H:K<+*5JM[RQ\PRDRYZ`9J020J14)@$#`F&$VG
MC7O;81@4,66CD[BWG.VHUL2,MS)F1VUR1=[1T<F()-C339``&9=-4``I3+G=
M',``)U#CJ#2QJ6B&9",PXX?1'4:BZ]"+S6&]7.ANU&XO$MH<1E$\9`REZ)0I
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M%3K3HIK5)=U3;:RFORY%U5,L!M?`D'',?>W0H.%>&O.F_>9^*^97,6]L%LG^
M)[/NNTK?L7$<;<1EEH^Y6T@4I'4E(^RT*9JYD#&%0?=,<H`6@#XZUI:&^FY-
MU5W4R5H!"2ULD=L_&(O4VN^G5OT<_HG0=/5H14J"G%5"@HYDX#++=*>'&%V[
MD?#O.'*A/CM-X-N;'EL7G@C+2&46KC(_ZRK"N742U*:(;`UA&3IP[`TBD0RJ
M9Q3**0"&ZHZ>7VAN-:MM5#R.8A<SS)RE+=+?/U16.E&M=-Z/;K;?J=NJ=HJN
MFY<F%)22<P,E%7NRG@,9RA.C6?WO"(&*&7.#1A`IMM;!O\2";^UN$RX#L*:E
M?&M--%(U>2`7:1-*,"&YYO"8]/9$N]<.AJU*6JDNS*3/'F)4!/`8`S,]D.!Y
M<<><T\G^"EZ<?Y">L9GFV^[#MN*G9XB4DQL`UVLY"%D9MTQ2(W=23:(7<,5O
MER;3'`IBUKXZG*VC55VL4B\5$>OC**5H?5FGM&=1D7ZW-5;E&PHY"M.Q'`\!
MQ[(=;@^RI+'6&,48[FU6SR8L'&]FVA*N68*BP<R-MVXQB'B[(5B)*F:N'#4Q
MDQ,4IMHA4-/*?/1T24K]IY``!]45?4E4U=[O6WI`FVZ^MQI/[)))F.W&(3>Y
M?VD[ZY'9PM#/?'J3M.W+@G7UN$S;`7"_>0T5<BUI2#-];EWM18-7OS4ZW9)G
M:+$4*7>`)G`X&`^ZF7W3"KA<FGF_A@@RV1Z*Z1]>DZ4TQ6:1OR2_1*84E@*_
M+*AB`<#M.\D=D=`'R:W^-?(5#YG]%^3WU"GO_(_+[J[*;=_CZ>GEJW_*K^4^
M4G[>3+/ME*/.G/;_`(O\S+\'YC/+LSSEZ(]53U&Z=`ZUK]E//3J(A[R19_)Y
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?CX@V;?&$79<A/EV^,9W]CR_+_;3I^^FC\SQAQOC_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
